Recipharm today announces that it has commenced negotiations with the pharmaceutical company LIDDS regarding collaboration on manufacture of Liproca Depot®ahead of continued clinical development and a potential future market launch.
In a joint letter of intent the companies have explained their intention to initiate collaboration regarding scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Such a collaboration will initially focus on Liproca®Depot, a targeted treatment for prostate cancer that is currently in Phase II, but it may also include other products based on LIDDS’ unique technology platform. The letter of intent follows a so-called feasibility study performed by Recipharm. The results of this study confirm the possibility of developing a process for manufacture that ensures a high-quality end product.
“Collaboration with a manufacturing partner as renowned as Recipharm increases the power of attraction of our prostate-cancer product Liproca®Depot. A high-quality and cost-effective manufacturing process increases the chances of in the future being able to offer better treatment to patients with prostate cancer,” says Monica Wallter, LIDDS’ CEO. “There is great potential in LIDDS’ technology platform for development of new treatments for diseases where local administration is desirable. We look forward to contributing with our technical expertise in the field of manufacture, so that cancer patients can in future be offered treatments associated with fewer side effects,” says Maria Lundberg General Manager Recipharm Pharmaceutical Development.
Contact information
Maria Lundberg, General Manager Recipharm Pharmaceutical Development, maria.lundberg@recipharm.com, + 46 8 6025 273
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
About LIDDS
LIDDS’ goal is to develop pharmaceutical products with fewer side effects for various forms of cancer. The company’s most advanced project – the prostate cancer product Liproca® Depot – has already displayed very good results in clinical trials. LIDDS’ unique drug-delivery technology releases drugs locally, close to the tumour, so as to reduce the side effects and the number of doses. The fact that LIDDS technology can utilise pharmaceutical substances already approved by authorities reduces the risk of development and the time and cost necessary to achieve marketing approval. For further information visit www.lidds.se
Help employers find you! Check out all the jobs and post your resume.
